KRBP vs. PALI, FRTX, TTNP, NSTGQ, CELZ, TCON, FNCH, TCBP, ALBT, and GMDAQ
Should you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Palisade Bio (PALI), Fresh Tracks Therapeutics (FRTX), Titan Pharmaceuticals (TTNP), NanoString Technologies (NSTGQ), Creative Medical Technology (CELZ), TRACON Pharmaceuticals (TCON), Finch Therapeutics Group (FNCH), TC Biopharm (TCBP), Avalon GloboCare (ALBT), and Gamida Cell (GMDAQ). These companies are all part of the "biological products, except diagnostic" industry.
Palisade Bio (NASDAQ:PALI) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
In the previous week, Palisade Bio had 3 more articles in the media than Kiromic BioPharma. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for Kiromic BioPharma. Kiromic BioPharma's average media sentiment score of 0.99 beat Palisade Bio's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 3.3% of Palisade Bio shares are held by company insiders. Comparatively, 20.6% of Kiromic BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Palisade Bio received 7 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. However, 50.00% of users gave Kiromic BioPharma an outperform vote while only 44.44% of users gave Palisade Bio an outperform vote.
Palisade Bio has higher revenue and earnings than Kiromic BioPharma. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Palisade Bio's return on equity of 0.00% beat Kiromic BioPharma's return on equity.
Palisade Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Palisade Bio presently has a consensus target price of $22.50, indicating a potential upside of 398.89%. Given Kiromic BioPharma's higher possible upside, equities research analysts clearly believe Palisade Bio is more favorable than Kiromic BioPharma.
Summary
Palisade Bio beats Kiromic BioPharma on 10 of the 15 factors compared between the two stocks.
Get Kiromic BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiromic BioPharma Competitors List
Related Companies and Tools
